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introduction: Iron overload is the main cause of morbidity and mortality in 
patients with β-thalassemia.
the aim: The aim of this study was to evaluate the prevalence of genetic 
markers (HFE mutations C282Y and H63D) among Egyptian β-thalassemic 
Children and its effect on their iron status. 
Patients and Methods: 59 β-thalassemic children attending the pediatric 
hematology clinic in Menoufiya University Hospital  (23  thalassemia major, 
23  thalassemia intermedia and13 thalassemia trait) with  50 apparently healthy, 
Egyptian children (control group) were screened for the prevalence of these 
two  mutations by digestion of PCR products (RFLP). Serum ferritin level was 
measured by ELISA. 
results: Neither carrier status for the C282Y allele nor homozygous status 
for the H63D allele were detected in any of the thalassemic children or the 50 
controls. The H63D heterozygous state was detected in 15 (25.4%) thalassemic 
patients with an allele frequency of 12.71% and in 11 (22%) controls with an 
allele frequency of 11%. with no significant difference between the thalassemic 
groups and the controls. The prevalence of carriers for the H63D mutation was 
26.1% with an allele frequency of 13.04% in patients with either β- thalassemia 
major or intermedia, while in β- thalassemia trait the prevalence of this mutation 
was 23.1% with an  allele frequency of 11.54%. There were significant higher 
levels of the mean yearly serum ferritin in both β-thalassemia major and 
intermedia patients who are heterozygotes for the H63D mutation compared 
to those without this mutation. The mean serum ferritin levels were positively 
correlated with the age of the patients. On the other hand, the prevalence of iron 
-induced complications was not statistically different between patients carrying 
or not carrying this mutation (among TM and TI).
conclusions: There is no difference  in the  prevalence of H63D mutation 
between β-thalassemic patients and the normal children and the presence of a 
heterozygous H63D status and older age are two risk factors for iron overload 
in Egyptian β-thalassemic children.
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introDUction                                       
The thalassemias are the commonest 
monogenic disorders in the world and 
globally it is estimated that there are 
270 million carriers, of which 80 mil-
lion are carriers of β-thalassemia.1 
β- Thalassemia is an autosomal reces-
sive disorder of hemoglobin synthesis. 
It is caused by a direct down-regulation 
in the synthesis of structurally normal 
β chains. Due to the excess of α-globin 
chains relative to β-globin chains; 
α-globin tetramers (α4) are formed, and 
these inclusions interact with the red 
cell membrane and shorten red cell sur-
vival, leading to anemia and increased 
erythroid production.2
The clinical manifestations of β- thalas-
semia are extremely diverse, spanning 
a broad spectrum from the transfusion-
dependant state of thalassemia major to 
asymptomatic state of thalassemia trait. 
Between these two clinical extremes 
lies the clinical syndrome of thalas-
semia intermedia which comprises a 
diverse spectrum of phenotypes from 
a condition that is slightly less severe 
than transfusion dependence to one 
that is asymptomatic and often identi-
fied through a routine blood test1. A 
common complication of β-thalassemia 
involves organ damage from iron over-
load (hemosidrosis) which is not only 
an inevitable consequence of prolonged 
transfusion therapy3 but also depends 
on the increased intestinal iron absorp-
tion which is proportional to the degree 
of erythroid hyperplasia.4
The major determinant of the clinical 
severity in thalassemia syndromes is 
the underlying mutations of the beta-
globin gene and the degree of iron 
overload. Patients who inherit two 
β-thalassemia (severe) mutations usu-
ally have β-thalassemia major (TM), 
a severe anemia requiring life-long 
treatment with blood transfusions to 
maintain satisfactory levels of hemo-
globin (Hb) and iron-chelation therapy 
to combat the tendency to iron over-
load. Patients who inherit milder muta-
tions may have β-thalassemia interme-
dia (TI). β-thalassemia heterozygotes 
(Thalassemia trait, TT) are normal or 
mildly anemic, with no clinical symp-
toms.5
The diversity of the β- thalassemias 
phenotypes likely relates to complex 
genetic interactions, many not yet de-
fined that underline these conditions, to-
gether with monogenetic, environmen-
tal modulators or modifiers6. Primary 
modifiers include the broad spectrum 
of β -thalassemia alleles (more than 200 
different alleles). Secondary modifiers 
include other genes involved in globin 
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chain synthesis e.g. α- thalassemia, he-
reditary persistent fetal Hb (HPFH) and 
other Hb variants known to modify the 
phenotype. Tertiary modifiers include 
loci not involved in globin synthesis but 
might modify the complications of the 
disease, these include genes affecting 
bilirubin level, genes involved in iron 
metabolism (Hereditary Hemochroma-
tosis), genes contributing to bone affec-
tions and genes contributing to suscep-
tibility to infection.7
Hereditary Hemochromatosis (HH) is 
an autosomal recessive disorder caused 
by mutations in the HFE gene. It is 
characterized by increased iron absorp-
tion and storage, resulting in progres-
sive and multisystem oxidative organ 
damage8. Two common HFE gene mis-
sense mutations, C282Y and H63D, 
have been described to be associated 
with the disease with different con-
tribution in different populations9-12. 
Several studies have tried to correlate 
iron status in thalassemic patients and 
the presence of one or both HFE gene 
mutations, C282Y and H63D12-17. To the 
best of our knowledge, there is no in-
formation regarding C282Y and H63D 
HFE gene mutation among Egyptian 
children with β-thalassemia. Only one 
publication18 studied the prevalence of 
these two mutations in Egyptians with 
HCV liver cirrhosis. The objectives 
of the present study were to study the 
prevalence of these two HFE gene mu-
tations in Egyptian β-thalassemic chil-
dren and to evaluate the effect of these 
two mutations on their iron status. 
PatientS anD MetHoDS                 
Subjects: Fifty nine β-thalassemic chil-
dren regularly attending the pediatric 
hematology clinic in Menoufiya Uni-
versity Hospital either for transfusion 
and chelation (23 TM and 23 TI) or for 
follow up of Hb level and iron status 
(13 patients with TT) were randomly 
selected for this study. 
Regarding TM patients they were 11 
males and 12 females aged 3-21 years 
(mean 9±5.23 years). These patients 
were treated to maintain the pre-trans-
fusional Hb level above 8 g/dl and post 
-transfusional Hb above 10 g/dl  by reg-
ular red blood cell concentrates transfu-
sion. 
Thalassemia intermedia (TI) patients, 
were 23 patients who regularly attend 
our hematology clinic for follow up and 
blood transfusion when needed. They 
were 11 males and 12 females aged 4-19 
years (mean 10.39±3.51 years). Twenty 
one of them were needed to be regularly 
transfused (every one or two months) to 
maintain their growth and only 2 were 
occasionally transfused.
Desferroxamine (DFO) 30-50mg/kg/
day was administered by subcutane-
ous infusions over 8-10 hours 5 nights 
/week. DFO was usually started when 
serum ferritin approximated 1000 ng/
ml19. Twenty one patients of TM group 
were under regular chelation and 2 did 
not need to start the chelation yet. Of  TI 
patients, 18 patients were regularly che-
lated by DFO and 5 did not need to start 
the chelation yet. For each regularly 
transfused patient (both for thalassemia 
major or intermedia) the mean amount 
of transfused RBCs (ml/kg/year) was 
calculated for the last 3 years.
For the chelated patients they were se-
lected as being well compliant with the 
chelation therapy. The mean index of 
observation (OI) for each patient during 
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the last three years was ≥ 80% which 
is calculated as follow: OI = (the actual 
received DFO dose ÷ the prescribed 
DFO dose) X100.17
Our study, also, involved 13 thalassemia 
trait children (4 males and 9 females) 
aged 3-18 years (mean, 8.50 ± 4 years). 
All of them were non anemic (mean Hb 
11.89 ± 0.47 gm/dl) with no previous 
history of iron therapy. They were se-
lected from the sibs of our thalassemia 
major and intermedia patients.
Fifty (28 males and 22 females) appar-
ently healthy, Egyptian children aged 6.5 
to 16.9 years (mean 10.24±2.96 years) 
were selected as a control group. Their 
Hb levels ranged from 12.0 to 14.5 g/
dl (mean 13±0.7g/dl).Their serum fer-
ritin levels were within normal range 
for their ages with mean of (82.2± 19.7 
ng/ml) with normal Hb electrophoresis. 
The Ethics Committee approved the 
study and informed written consent was 
obtained from all patients and controls 
or their parents.
evaluation of iron Status: Serum fer-
ritin level was used to estimate the iron 
status of our patients. The mean serum 
ferritin level in the previous 3 years 
was considered (on the average of 3 
determinations yearly) for each patient. 
We excluded the results obtained when 
there was active liver disease (elevated 
ALT and AST) or any acute or chronic 
inflammatory illness. Serum ferritin was 
measured by Enzyme Linked Immune 
Sorbent Assay (ELISA) technique. 
Detection of HFe gene Mutations: 
Blood samples were drawn from pa-
tients with β- thalassemia major and 
intermedia immediately before their 
blood transfusion session. 
DNA was extracted from both control’s 
and patient’s leukocytes according to 
the method of Al-Janabi and Martinez20.
Two single Polymerase chain reactions 
(PCR) were performed to amplify rele-
vant segments of the HFE gene that car-
ry the H63D and C282Y mutation sites 
using the primers described by Feder et 
al21. PCR was performed using a Perkin 
Elmer Thermal Cycler Gen Amp 9700 
(Applied Biosystems, UK). A total vol-
ume of 25 µl PCR reaction containing 
100 ng of genomic DNA, 20 pmol of 
each primer, 200 µM of each dNTPs 
and 1.25 units of AmpliTaq Gold DNA 
polymerase (Applied Biosystems).
PCR cycles were one cycle at 95oC for 
10 minutes, to activate the AmpliTaq 
Gold and to initial denature the DNA, 
followed by 32 cycles of 94oC for 30 
seconds, 58oC for 30 seconds and 72 
oC for 30 seconds and a final extension 
step of 72oC for 5 minutes. Ten micro-
leters of the PCR products were sub-
sequently digested with the restriction 
enzymes RsaI (C282Y mutation) and 
MboI (H63D mutation). The digestion 
products were electrophoresed on a 3% 
gel (1:1 agarose/Nusiev). Amplification 
with the primers for codon 282 pro-
duced a 390 bp fragment which is cut 
into 250 and 140 bp fragments in the 
wild allele while the mutant allele will 
be cut into 250, 111 and 29 bp. On the 
other hand, the H63D mutation abolish-
es the MboI recognition site in the 208 
bp PCR product: While normal DNA is 
cut into two fragments (70 and 138 bp), 
the mutated DNA is not cut.22
Statistics: Results were collected, 
tabulated, statistically analyzed by 
IBM personal computer and Statisti-
cal Package for the Social Sciences 
(SPSS) version 11. Differences between 
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and within the groups were evaluated 
by the non-parametric Mann-Whitney 
test. Chi-square test (χ2) was used to 
study the relation between two qualita-
tive variables. Kruskal- Wallis test (non 
-parametric test): Is a test of significance 
used for comparison between three or 
more groups not normally distributed 
having quantitative variables. Pearson - 
correlation (r): is a test used to measure 
the association between two quantita-
tive variables. Multiple linear regres-
sion analysis test was used to study the 
risk factors -A P-value of < 0.05 was 
considered statistically significant.23
reSUltS:                                                 
The C282Y mutation was not present 
in any of the 59 β-thalassemia patients 
or the 50 controls. The H63D heterozy-
gous state was detected in 15 (25.4%) 
thalassemic patients with allele fre-
quency of 12.71% of the tested chro-
mosomes and in 11 (22%) controls with 
allele frequency of 11%. There was no 
significant difference between the thal-
assemic group and the control group 
regarding the prevalence of H63D mu-
tation. The prevalence of carriers for 
the H63D mutation was 26.1% with an 
allele frequency of 13.04% in patients 
with either β-thalassemia major or inter-
media, while in β- thalassemia trait the 
prevalence of this mutation was 23.1% 
with an allele frequency of 11.54%. The 
age of first transfusion was significantly 
lower in TM in comparison with TI pa-
tients. On the other hand, the amount of 
transfused RBCs (ml/kg/year) was sig-
nificantly higher in TM in comparison 
with TI patients. There were no signifi-
cant differences between TM and TI pa-
tients regarding the mean serum ferritin 
level (Table 1).
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11 12 6 17 6 17
TT 8.5 ± 4.0 ----------- ------------ 89.8±27.5
Median=98
------- 4 9 2 11 3 10
Control 10.24±2.96 ----------- ------------- 82.2± 19.7 ------- 28 22 11 39
P value P>0.05 *P<0.001 *P<0.001  P1>0.05
*P2<0.001
P>0.05 P>0.05 P>0.05
*= Significant, P1 = comparison between TM and TI, P2 = comparison between both TM and TI in one 
side and TT and the control in other side
H/D= Heterozygote for the mutant H63D allele , H/H =Homozygote for the normal wild H63D allele 
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In both TM and TI groups the mean 
serum ferritin (ng/ml) was significantly 
higher in patients who were H63D 
heterozygous compared to H63H 
homozygotes (p <0.05). However 
there was no significant difference 
between H63D heterozygotes and 
H63H homozygotes regarding the 
age of first transfusion, the amount of 
transfused RBCs (ml/kg/year), the OI 
(%) or the presence of iron overload 
complications. On the other hand, 
there was no significant difference 
between mean serum ferritin in H63D 
heterozygotes and H63H homozygotes 
thalassemia trait patients (Table 2).
table 2: Relationship between H63D genotype and serum ferritin, mean transfused RBCs 














































79.1±14.5 88.5±5.8 90.4±30.3 3 (6.5%)
P value *P<0.01 P>0.05 P>0.05 *P<0.05 P>0.05 P>0.05 P>0.05 P>0.05
* = Significant
H/D= Heterozygote for the  mutant H63D allele, 
H/H =Homozygote for the normal wild H63D allele.
There were significantly positive correlations between serum ferritin levels and the 
age of patients in all thalassemia groups (TM, TI and TT) (Table 3). 
table 3: Correlation (r) between serum ferritin and age (yr), (for TM,TI&TT) age of 1st 
transfusion (yr), amount of transfused RBCs (ml/kg/yr) and OI (%) in thalassemia major 
and intermedia patients.
correlation between ferritin level 
(ng/ml) and:






r P value r P value r
P 
value
Age (yr) 0.83 * <0.001 0.62 * <0.05 0.75 *<0.01
Age of 1st transfusion 0.17 >0.05 0.57 >0.05
Amount of transfused RBCs (ml/kg/yr) 0.25 >0.05 0.04 >0.05
OI (%) -0.35 >0.05 -0.04 >0.05
* = Significant
Multiple linear regression analysis 
showed that the older age followed 
by the presence of H63D mutation in 
heterozygote state, (among both TM 
and TI) are the most important risk 
factors for iron overload, as indicated 
by serum ferritin level followed by the 




DiScUSSion                                             
The allelic frequencies of C282Y and 
H63D are widely variable between 
different populations. That of C282Y 
ranged from 0% to 9.9% with this al-
lele seen to be nearly 0% in North Af-
rican population. On the other hand, 
the allelic frequency of H63D in dif-
ferent populations ranged from 0% to 
20.4%11,24-26. In the present study, nei-
ther carrier for the C282Y allele nor 
homozygosity for H63D mutation was 
detected in any of studied controls or 
thalassemic patients. The prevalence of 
H63D mutation heterozygosity among 
controls was 22% (with allele fre-
quency of 11%). For the studied thalas-
semia patients the prevalence of H63D 
heterozygosity was 25.42% with allele 
frequency of 12.71%. Published data 
regarding H63D and C282Y allele fre-
quency among Egyptian population are 
scars. The only published data was that 
of Settin et al.18 who studied HFE gene 
mutations in Egyptians with hepatitis C 
virus infection with liver cirrhosis. They 
stated that HFE gene analysis showed 
that the abnormal C282Y was not de-
tected among patients or controls where-
as; the prevalence of heterozygosity for 
H63D allele was noted to be similar in 
controls (21.2%) and in cases (20.0%). 
These results are in accordance with 
our results. In this study the prevalence 
of H63D heterozygosity among both 
TM and TI groups was 26.1% (6 out of 
23 patients in each group) with H63D 
allele frequency of 13.04% (6 out of 46 
tested chromosomes in each group). In 
individuals with β- thalassemia trait the 
prevalence of this mutation was 23.1% 
(3 out of 13 tested patients) with allele 
frequency of 11.54% (3 out of 26 tested 
chromosomes) with no significant dif-
ference in allele frequencies between 
the all studied groups (Table 1). There 
was no significant difference in C282Y 
or H63D allele frequencies between the 
thalassemic group as a whole or any of 
the thalassemia groups (TM,TI or TT) 
and the controls. This is in agreement 
with what was reported that there is no 
difference regarding HFE frequency 
among thalasemic patients (TM4 or 
TT15) compared to normal population 
but against what was reported by others 
that HFE mutations C282Y and H63D 
are more frequent in BTM patients14,17, 
in BTI27 and in TT12,14 than in the nor-
mal population.
Some of thalassemia patients develop 
iron overload even without erythro-
cyte transfusions. If transfusions are 
needed, they will add more to the body 
iron excess28. This discordant course 
between individuals with the same he-
table 4: Multiple linear regression analysis for risk factors affecting serum ferritin in patients 






Constant -505.046 1398.893 -0.361 > 0.05
Age( yr) 132.034 16.628 0.731 7.94 *0.000
Amount of  transfused BCs (ml/kg/yr) 5.915 1.222 0.444 4.839 *=0.000
OI (%) -4.901 14.332 -0.031 -0.342 >0.05
H63D mutation 802.682 142.288 0.469 5.641 *=0.000
* = Significant
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matological alteration of thalassemia 
is very common and may be related to 
the different inherited mutations12. The 
presence of HFE gene mutations may 
adversely affect the course of a num-
ber of disorders including thalassemia. 
Data on the interaction of primary or 
hereditary hemochromatosis (HH) in 
thalassemic patients are scanty.4 
Although it was shown to be a poor 
predictor of iron load as it is affected 
by other conditions like infections or 
inflammation, liver disease or vitamin 
C deficiency, periodic assessment of se-
rum ferritin level is still the widely and 
most commonly used method to asses 
and monitor iron load in thalassemic 
children29. We considered it as the in-
dicator of iron load in this study. Many 
similar studies consider the mean serum 
ferritin level as indicator of iron over-
load in thalassemic children tested for 
HFE mutations.12,13,17
The results revealed a statistically sig-
nificant higher serum ferritin levels in 
patients with either β-thalassemia ma-
jor or intermedia who were heterozy-
gotes for H63D mutation compared to 
patients who did not have it (i.e. H63H 
homozygotes) (Table 2). 
Data on the interaction of primary 
hemochromatosis gene (HFE gene) mu-
tations in thalassemia patients are con-
troversial. Some researchers showed 
that the coexistence of HFE mutations 
in thalassemic patients may lead to se-
vere iron overload12,15,27 while others 
did not4,14,16,17,30,31. This controversy may 
be due to differences in clinical status 
and inclusion criteria, especially the 
age since first transfusion, between dif-
ferent studies. Moreover, the presence 
of other unknown iron-related gene (s) 
or HFE mutations could play a role in 
populations with a low prevalence of 
the known HFE mutations.
Comparison of the severity of iron 
overload among transfused thalassemic 
patients (either major or intermedia) is 
a complex issue. Several factors influ-
ence the iron burden in these subjects, 
including the transfusion protocol and 
compliance of chelation therapy4. Us-
ing a homogenous transfusion proto-
col for every group and selection of 
good compliant patients for chelation 
(OI>80%) helped minimizing the ef-
fects of these variables. Moreover, the 
comparable Hb  levels in patients with 
and without the mutation exclude the 
possibility that the difference in ferritin 
levels is due to the degree of anemia 
which may influence iron absorption. 
Our results confirm the hypothesis that 
in some way the H63D mutation could 
be implicated in increasing iron storage 
when in interaction with other genetic 
determinants.32
In this study there was no statistically 
significant difference in prevalence of 
iron overload complications in thalas-
semic patients (TM and TI) regarding 
H63D genotype (Table 2). It was re-
corded that although the levels of se-
rum ferritin, serum iron and transferrin 
saturation are higher than normal in 
heterozygotes for HH, complications 
due to iron overload are extremely rare 
in these individuals28. This can be ex-
plained by the fact that these complica-
tions need long time to be manifested. 
Moreover, our studied patients were 
good chelated with good compliance 
for DFO, suggesting that the optimal 
medical treatment is able to overcome 
the potential adverse effect on iron ab-




In this study, there was significant posi-
tive correlation between the age and 
the mean serum ferritin in each TM, TI 
and TT groups (Table 3). Moreover, the 
multiple linear regression analysis for 
risk factors affecting serum ferritin  in 
our patients revealed that the most im-
portant risk factors for iron overload 
among transfused thalassemia patients 
(TM and TI) were older age followed 
by presence of the H63D mutation in 
the heterozygote state and then the 
amount of transfused RBCs (ml/kg/
yr) (t=7.94 p<0.000, t=5.641 p=0.000, 
t=4.839  p=0.000 respectively). This 
reflects the cumulative effect of both 
transfusion (in transfused patients ) and 
intestinal iron absorption as iron tends 
to increase with age.34
In our thalassemia trait patients there 
was no significant difference in the 
mean serum ferritin level between 
(H63D) and H63H patients (Table 2). 
This is in agreement with previous 
studies14,16,31. On the other hand, other 
studies showed that heterozygosity for 
H63D is a risk factor for iron overload 
in thalassemia trait patients15. While 
others stated that beta-thalassemia 
carriers who are homozygotes for the 
H63D mutation had higher ferritin lev-
els than beta-thalassemia carriers with 
the H/H genotype, suggesting that the 
H63D mutation may have a modulating 
effect on iron absorption.13
conclUSion                                      
There is no difference regarding the HFE 
mutations between thlassemic children 
compared to normal’s and the presence 
of a heterozygous H63D mutation and 
older age are two risk factors for iron 
overload in Egyptian β-thalassemic 
children. Our study supports the emerg-
ing importance of genetic screening for 
this mutation in thalassemic children 
and in other iron-loading conditions. 
This may improve the quality of life in 
these patients by frequent follow up for 
earlier detection of iron overload and 
its complications and by implementing 
more aggressive iron chelating proto-
cols. 
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